MIMS news

Do not start any new course of ulipristal for fibroids, MHRA advises

Do not start any new course of ulipristal for fibroids, MHRA advises

New temporary safety measures have been introduced...

First treatment for primary progressive MS launched

First treatment for primary progressive MS launched

Ocrevus (ocrelizumab) is the first disease-modifying...

Don't prescribe antibiotics for most sore throats, says NICE

Don't prescribe antibiotics for most sore throats, says NICE

New guidance from NICE says healthcare professionals...

New low-dose levonorgestrel IUS provides five years' contraceptive cover

New low-dose levonorgestrel IUS provides five years' contraceptive cover

Kyleena is a new smaller-framed intrauterine system...

Help cancer patients live longer by offering smoking cessation support, GPs urged

Help cancer patients live longer by offering smoking cessation support, GPs urged

GPs could help patients diagnosed with lung cancer...

New MIMS workshop announced launching the 2018 'Respiratory and Allergy Learning Series'

New MIMS workshop announced launching the 2018 'Respiratory and Allergy Learning Series'

A free full-day MIMS workshop has just been launched...

Experts back e-cigarette use for smoking cessation

Experts back e-cigarette use for smoking cessation

Switching from normal cigarettes to e-cigarettes has...

New analgesic combines an opiate with an NSAID

New analgesic combines an opiate with an NSAID

Skudexa is an oral analgesic containing a combination...

Prepare for your appraisal with MIMS Learning

Prepare for your appraisal with MIMS Learning

In the run-up to appraisal, MIMS Learning can help...

GPs asked for opinions on restricting OTC prescribing

GPs asked for opinions on restricting OTC prescribing

NHS England has launched a consultation on proposals...

New once-daily triple combination inhaler for COPD

New once-daily triple combination inhaler for COPD

Trelegy Ellipta is the second 3-in-1 treatment for...

New obesity treatment rejected by NICE

New obesity treatment rejected by NICE

The obesity treatment naltrexone/bupropion (Mysimba)...

New MIMS table helps GPs adjust antidiabetic doses in renal impairment

New MIMS table helps GPs adjust antidiabetic doses in renal impairment

Prescribers can now consult a handy MIMS table to check...

First NICE asthma guideline recommends oral treatment before LABA

First NICE asthma guideline recommends oral treatment before LABA

NICE suggests offering a leukotriene receptor antagonist...

Dupilumab: first biologic for moderate-to-severe atopic dermatitis

Dupilumab: first biologic for moderate-to-severe atopic dermatitis

Dupilumab (Dupixent) is the first biologic treatment...

GPs should no longer prescribe 18 'low value' treatments, NHS England rules

GPs should no longer prescribe 18 'low value' treatments, NHS England rules

NHS England believes cutting access to the treatments,...

Sildenafil to be available over the counter

Sildenafil to be available over the counter

Men with erectile dysfunction (ED) will be able to...

Antiepileptic prescribing advice updated

Antiepileptic prescribing advice updated

Prescribers should take patient-related factors into...

Prescribe quinine with caution in patients at risk of QT prolongation, MHRA advises

Prescribe quinine with caution in patients at risk of QT prolongation, MHRA advises

New advice highlights that quinine can have effects...

Guselkumab further extends choice in psoriasis prescribing

Guselkumab further extends choice in psoriasis prescribing

Tremfya (guselkumab) is licensed for the treatment...

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more